跳至主要内容
临床试验/NCT07751913
NCT07751913尚未招募不适用

Validation of the ProNephro AKITM (NGAL) in Adult ICU Patients in the ICU at Risk of Moderate to Severe Acute Kidney Injury (ALPACA)

BioPorto Diagnostics0 个研究点目标入组 800 人开始时间: 2026年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
800
主要终点
Sensitivity of the ProNephro AKI™ Urinary NGAL Test at the 172 ng/mL Cut-off

研究概览

简要总结

The purpose of this study is to evaluate the performance of the ProNephro AKI™ (NGAL) test for identifying critically ill adults at risk of developing moderate to severe acute kidney injury (KDIGO Stage 2/3) within 48 to 72 hours of ICU admission.

The study will assess how accurately the test predicts acute kidney injury by evaluating its sensitivity, specificity, positive predictive value, and negative predictive value. Participants will provide blood and urine samples for testing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females ≥ 22 years of age. Subjects must be admitted or admission pending to an Intensive Care Unit and must have a urine sample collected within 24 hours of ICU admission.
  • Subjects must have at least one of the following, leading to admission to the ICU, or occurring within 24 hours of admission to the ICU (unless otherwise specified):
  • Vasoactive medication administration Mechanical ventilation Hypoxemia requiring oxygen support therapy including Bilevel positive airway pressure (BIPAP) and high flow nasal canula Serum Lactate greater than 2.5 mmol/L, within 6 hours prior to enrollment History (any) of solid organ transplantation, renal transplantation included only if more than 3 months prior History (any) of bone marrow transplantation Ability to provide written informed consent

排除标准

  • Special populations including pregnant and lactating women, prisoners, or institutionalized individuals.
  • Subjects receiving Kidney Replacement Therapy in the first 24 hours of ICU admission.
  • Subjects diagnosed with active Urinary Tract Infection per institute standard of care at the time of NGAL sampling.
  • Subjects with a known history of chronic kidney disease stages 4 or 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL/min/1.73m
  • Subjects with any known urothelial, urological or kidney malignancies.
  • Subjects that have had any of the following urologic procedure or urologic surgery within 30 days prior to ICU admission:
  • Nephrostomy or nephroureteral stent placement Ureteral stent placement or exchange Ureteroscopy Lithotripsy Transurethral resection of the prostate Transurethral resection of bladder tumor Renal biopsy Subjects that have had surgical nephrectomy less than 3 months prior to admission.
  • Subjects that have been previously enrolled in this study. Subjects enrolled in an interventional pharmaceutical or device clinical trial ICU admission.

结局指标

主要结局

Sensitivity of the ProNephro AKI™ Urinary NGAL Test at the 172 ng/mL Cut-off

时间窗: T0 urine specimen collected within 24 hours of ICU admission; AKI status assessed at 48 to 72 hours after ICU admission

Percentage of evaluable participants with independently adjudicated KDIGO Stage 2 or Stage 3 acute kidney injury at 48 to 72 hours who have a T0 urinary NGAL concentration of 172 ng/mL or greater, as measured using the ProNephro AKI™ assay.

Specificity of the ProNephro AKI™ Urinary NGAL Test at the 172 ng/mL Cut-off

时间窗: T0 urine specimen collected within 24 hours of ICU admission; AKI status assessed at 48 to 72 hours after ICU admission

Percentage of evaluable participants without independently adjudicated KDIGO Stage 2 or Stage 3 acute kidney injury at 48 to 72 hours who have a T0 urinary NGAL concentration below 172 ng/mL, as measured using the ProNephro AKI™ assay.

Positive Predictive Value of the ProNephro AKI™ Urinary NGAL Test at the 172 ng/mL Cut-off

时间窗: T0 urine specimen collected within 24 hours of ICU admission; AKI status assessed at 48 to 72 hours after ICU admission

Percentage of evaluable participants with a T0 urinary NGAL concentration of 172 ng/mL or greater who have independently adjudicated KDIGO Stage 2 or Stage 3 acute kidney injury at 48 to 72 hours, as measured using the ProNephro AKI™ assay.

Negative Predictive Value of the ProNephro AKI™ Urinary NGAL Test at the 172 ng/mL Cut-off

时间窗: T0 urine specimen collected within 24 hours of ICU admission; AKI status assessed at 48 to 72 hours after ICU admission

Percentage of evaluable participants with a T0 urinary NGAL concentration below 172 ng/mL who do not have independently adjudicated KDIGO Stage 2 or Stage 3 acute kidney injury at 48 to 72 hours, as measured using the ProNephro AKI™ assay.

次要结局

  • Correlation Between Urinary and Plasma NGAL Concentrations Measured Using the ProNephro AKI™ Assay(Across protocol-defined collection time points through 72 hours after ICU admission)
  • Agreement Between Urinary and Plasma NGAL Concentrations Measured Using the ProNephro AKI™ Assay(Across protocol-defined collection time points through 72 hours after ICU admission)
  • Change in Urinary NGAL Concentration Over Time by KDIGO Stage 2/3 Acute Kidney Injury Status(From T0 specimen collection through 72 hours after ICU admission)
  • Percentage of Participants Developing KDIGO Stage 2/3 Acute Kidney Injury by Sequential Urinary NGAL Pattern(From T0 specimen collection through assessment of acute kidney injury status at 72 hours after ICU admission)

研究者

发起方
BioPorto Diagnostics
申办方类型
Industry
责任方
Sponsor

相似试验